© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, UroGen Pharma Ltd. (URGN) shows an Average True Range (ATR) of 1.36 and an Enterprise Value of 489.27M. Its average trading volume over the past 3 months is 704.47K, indicating liquidity. These fundamental metrics provide insight into URGN's underlying financial health and market activity.
| ATR | 1.36 |
| Enterprise Value | 489.27M |
| Avg Vol (3 Months) | 704.47K |
| Avg Vol (10 Days) | 488.05K |
UroGen Pharma Ltd. (URGN) technical indicators as of February 27, 2026: the SMA 20 is 1.62%, SMA 50 at -1.01%, and SMA 200 at 16.58%. The RSI 14 value is 51.02, suggesting its current momentum. These technical analysis signals help assess URGN's price trends and potential future movements.
| SMA 20 | 1.62% |
| SMA 50 | -1.01% |
| SMA 200 | 16.58% |
| RSI 14 | 51.02 |
UroGen Pharma Ltd. (URGN) stock performance overview as of February 27, 2026: The 52-week high is $30 (currently -29.4% below), and the 52-week low is $3.42 (currently 519.3% above). Over the past year, URGN's performance is 83.75%, compared to the S&P 500's 10.89% change.
| 52-Week High | 30 |
| 52-Week High Chg | -29.40% |
| 52-Week Low | 3.42 |
| 52-Week Low Chg | +519.30% |
| S&P 500 52-Week Chg | 10.89% |
According to market data, UroGen Pharma Ltd. (URGN) stock's recent performance metrics show that over the last month, URGN is -14.54%, with a Year-to-Date (YTD) performance of -17.46%. Over the past year, the stock has seen a 83.75% change. These figures summarize URGN's price movements across various periods, reflecting its historical returns.
| Period | 1 Week | 1 Month | Quarter | Half Year | 1 Year | YTD |
|---|---|---|---|---|---|---|
| High | 22.02 | 22.5 | 30 | 30 | 30 | 24.1 |
| Low | 19.91 | 19.13 | 18.12 | 15.86 | 3.42 | 18.12 |
| Performance | -9.88% | -14.54% | +14.04% | +25.03% | +83.75% | -17.46% |
According to current financial data, URGN stock's P/E (TTM) ratio is -8.85, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.23. Key valuation ratios for URGN, including P/S (13.67), P/B (-8.79), and P/FCF (-7.16), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.
| Valuation | URGN | Sector Median | Industry Avg | S&P 500 |
|---|---|---|---|---|
| P/E (TTM) | -8.85 | -1.23 | -5.16 | 32.59 |
| P/S (TTM) | 13.67 | 3.71 | 464.92 | 5.98 |
| P/B (TTM) | -8.79 | 0 | 6.39 | 4.86 |
| P/FCF (TTM) | -7.16 | -351.13 | -235.77 | 30.98 |